Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Plos Genetics|December 5, 2012
Population-based resequencing of APOA1 in 10,330 individuals: spectrum of genetic variation, phenotype, and comparison with extreme phenotype approachChristiane L Haase, Ruth Frikke-Schmidt, Børge G Nordestgaard, et al.
Diabetes|May 15, 2015
HDL Cholesterol and Risk of Type 2 Diabetes: A Mendelian Randomization StudyChristiane L Haase, Anne Tybjærg-Hansen, Børge G Nordestgaard, et al.
International Journal of Colorectal Disease|October 23, 2013
Recurrence after endoscopic mucosal resection-therapy failure?S Belle, L Haase, L R Pilz, et al.
Obesity Science & Practice|April 12, 2021
Body mass index and risk of obesity-related conditions in a cohort of 2.9 million people: Evidence from a UK primary care databaseChristiane L Haase, Kirsten T Eriksen, Sandra Lopes, et al.
Mayo Clinic Proceedings|August 11, 2023
Obesity, Cardiorenal Comorbidities, and Risk of Hospitalization in Patients With Heart Failure With Preserved Ejection FractionCamilla S Morgen, Christiane L Haase, Tugce K Oral, et al.
The Journal of Clinical Endocrinology and Metabolism|November 18, 2011
LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individualsChristiane L Haase, Anne Tybjærg-Hansen, Abbas Ali Qayyum, et al.
Obesity Science & Practice|April 12, 2021
Body mass index trajectories among people with obesity and association with mortality: Evidence from a large Israeli databaseOrna Reges, Dror Dicker, Christiane L Haase, et al.
Circulation. Cardiovascular Genetics|August 12, 2011
Heterozygosity for R1141X in ABCC6 and risk of ischemic vascular diseaseLouise S Hornstrup, Anne Tybjærg-Hansen, Christiane L Haase, et al.
International Journal of Epidemiology|November 2, 2014
Subgroups at high risk for ischaemic heart disease:identification and validation in 67 000 individuals from the general populationRuth Frikke-Schmidt, Anne Tybjærg-Hansen, Greg Dyson, et al.
Obesity Science & Practice|September 3, 2020
Real-world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support programSean Wharton, Christiane L Haase, Elham Kamran, et al.
Pageof 5